Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
1998-7-1
pubmed:abstractText
To evaluate the toxicity, immunogenicity, and pharmacokinetics of a human-mouse chimeric monoclonal antibody (mAb) ch 14.18 directed against disialoganglioside (GD2) and to obtain preliminary information on its clinical efficacy, we conducted a phase I trial in 10 patients with refractory neuroblastoma and one patient with osteosarcoma.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0732-183X
pubmed:author
pubmed:issnType
Print
pubmed:volume
16
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2169-80
pubmed:dateRevised
2011-7-29
pubmed:meshHeading
pubmed-meshheading:9626218-Adult, pubmed-meshheading:9626218-Animals, pubmed-meshheading:9626218-Antibodies, Monoclonal, pubmed-meshheading:9626218-Child, pubmed-meshheading:9626218-Child, Preschool, pubmed-meshheading:9626218-Complement C3, pubmed-meshheading:9626218-Complement C4, pubmed-meshheading:9626218-Complement Hemolytic Activity Assay, pubmed-meshheading:9626218-Female, pubmed-meshheading:9626218-Fluorescent Antibody Technique, Indirect, pubmed-meshheading:9626218-Gangliosides, pubmed-meshheading:9626218-Humans, pubmed-meshheading:9626218-Infusions, Intravenous, pubmed-meshheading:9626218-Male, pubmed-meshheading:9626218-Mice, pubmed-meshheading:9626218-Neuroblastoma, pubmed-meshheading:9626218-Osteosarcoma, pubmed-meshheading:9626218-Pain, pubmed-meshheading:9626218-Recombinant Fusion Proteins, pubmed-meshheading:9626218-Treatment Outcome
pubmed:year
1998
pubmed:articleTitle
Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.
pubmed:affiliation
Department of Pediatrics, University of California San Diego 92103-8447, USA. alyu@ucsd.edu
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't, Clinical Trial, Phase I